New pancreatic cancer drug carries a $39,800 monthly list price: What to know

Live updates

1. 16d ago

   FDA approves RASONQUE for pancreatic cancer with $39,800 monthly price

   The FDA has granted speedy approval to daraxonrasib, marketed as RASONQUE, a pancreatic cancer drug developed by Revolution Medicines. The treatment costs $39,800 per month. Clinical data shows the drug improves patient survival and extends lives for those with a disease known for high mortality rates. Market analysts expect the drug to become a blockbuster for the independent developer. While the approval is described as a landmark moment by researchers, some critics argue that potential government budget cuts could limit patient access to the therapy.

   Why it matters

   Pancreatic cancer typically has high mortality rates and few effective therapeutic options. Revolution Medicines remained an independent company during the development of this breakthrough. The drug's arrival provides a new survival-improving option for patients.

   What is confirmed

   • The FDA approved daraxonrasib, marketed as RASONQUE, to treat pancreatic cancer.
   • RASONQUE carries a monthly list price of $39,800.
   • The drug has shown to improve survival and extend patients' lives.
   • Revolution Medicines developed the drug.

   Still unconfirmed

   • Budget cuts proposed by Donald Trump could threaten patient access to the drug.
   • A Boston researcher described the FDA approval as an exceptional moment.

   What to watch next

   • Insurance coverage determinations for the $39,800 monthly cost
   • Long-term survival data from expanded patient populations
   • Revenue reports from Revolution Medicines to confirm blockbuster status
   Sources used for this update (6)

   1. The Washington Post — FDA approves ‘landmark’ pancreatic cancer drug that extends patients’ lives
   2. Reuters — Revolution's lifesaving pancreatic cancer drug wins speedy FDA approval
   3. NPR — FDA approves landmark pancreatic cancer drug that's shown to improve survival
   4. WSJ — Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent
   5. CBS News — Pancreatic cancer drug approved by FDA is "exceptional moment," Boston researcher says
   6. MS NOW — Opinion | Trump’s cuts threaten access to a life-saving pancreatic cancer drug
   confidence 95%
2. 18d ago

   FDA Approves Pancreatic Cancer Drug RASONQUE

   The FDA has approved daraxonrasib, marketed as RASONQUE, to treat pancreatic cancer. The drug carries a monthly list price of $39,800. Analysts expect the treatment to become a blockbuster for Revolution Medicines, the developer of the drug. This approval provides a new therapeutic option for a disease characterized by high mortality rates.

   Why it matters

   Pancreatic cancer is known as a deadly disease with limited treatment options. The introduction of a breakthrough drug like daraxonrasib represents a shift in the medical approach to this specific malignancy.

   What is confirmed

   • The FDA approved the drug daraxonrasib for the treatment of pancreatic cancer.
   • The brand name for daraxonrasib is RASONQUE.

   Still unconfirmed

   • Revolution Medicines has a market valuation of $47 billion.

   What to watch next

   • Insurance coverage determinations for the $39,800 monthly cost.
   Sources used for this update (7)

   1. WSJ — FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease
   2. BBC — FDA approves breakthrough drug daraxonrasib to treat pancreatic cancer
   3. Pancreatic Cancer Action Network — FDA Approves RASONQUE™ (daraxonrasib)
   4. The New York Times — The Race to Develop More Medicines Like the New Pancreatic Cancer Drug
   5. Yahoo Finance — New pancreatic cancer drug carries a $39,800 monthly list price: What to know
   6. BioPharma Dive — Revolution pancreatic cancer drug should quickly become a blockbuster, analysts say
   7. www.insidermonkey.com — Revolution Medicines (RVMD) Made Pancreatic-Cancer History. At $47B Valuation, the Market Already Assumed It
   confidence 90%